Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Transition Bio is raising $30,555,975.00 in new funding. Sources indicate as part of senior management Co-Founder, Samuel Cohen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Transition Bio

Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through our Condensomics platform, our goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. We harness droplet microfluidic approaches and cellular platforms to characterize condensates with unprecedented scale and precision, resulting in the mapping of condensates and their modulation, in molecular detail. Our proprietary datasets feed in to algorithms that we use for target discovery, target validation and drug design.

To learn more about Transition Bio, visit http://www.transitionbio.com/

Contact:
Samuel Cohen, Co-Founder
917-445-5573
scohen@transitionbio.com
https://www.linkedin.com/in/samuel-cohen-3b301816/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved